Incidence of Cross Resistance Between Rifampicin and Rifabutin in Mycobacterium tuberculosis Strains in Izmir, Turkey

References

• Yuen LK, Leslie D, Cole PJ. Bacteriological and molecu-lar analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol 1999; 37 (12): 3844–3850.
   PubMed Web of Science ®Google Scholar
• Pfyffer GE, Bonato DA, Ebrahimzadeh A et al. Multicenter laboratory validation of testing of Mycobacterium tuberculosis against classical second-line and newer antimicro-bial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microbiol 1999; 37 (10): 3179-3186.
   PubMed Web of Science ®Google Scholar
• Heifets LB, Linholm-Levy PJ, Iseman MD. Rifabutin: Minimum inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1988; 137 (3): 719–721.
   PubMed Web of Science ®Google Scholar
• Della Bruna C, Olliaro P. Setting breakpoints for assess-ing the sensitivity of mycobacteria to rifabutin in vitro. J Antimicrobial Chem 1994; 34 (1): 184–186.
   PubMed Web of Science ®Google Scholar
• Farr BM: Rifamycins. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone. 1995: 318–25.
   Google Scholar
• Uzun M, Erturan Z, Ang O. Investigation of cross-resis-tance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002; 6 (2): 164–165.
   PubMed Web of Science ®Google Scholar
• Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 Suppl. 1: S3-14.
   Google Scholar
• Heifets LB, Iseman MD. Determination of in vitro sus-ceptibility of Mycobacteria to ansamycin. Am Rev Respir Dis 1985; 132 (3): 710–711.
   PubMedGoogle Scholar
• Hershfield EB: Tuberculosis. Treatment. Can Med Assoc J 1999; 161 (4): 405-411.
   Google Scholar
• Luna-Herrera J, Reddy MV, Gandgadharam PR. In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli. J Antimicrob Chem 1995; 36 (2): 355–363.
   PubMed Web of Science ®Google Scholar
• Yew WW, Chau CH. New antimycobacterial agents. Mon Arch Chest Dis 1996; 51 (5): 394–404.
   PubMedGoogle Scholar
• World Health Organization: Global tuberculosis control: surveillance, planning, financing: WHO report 2004: 171.
   Google Scholar
• Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant tuberculosis. Eur Respir J 2002; 20 Suppl 1: 66–77.
   PubMedGoogle Scholar
• Kisa O, Albay A, Baylan O et al. Drug resistance in Mycobacterium tuberculosis: a retrospective study from a 2000-bed teaching hospital in Ankara, Turkey. Int J Antimicrob Agents 2003; 22 (4): 465-457.
   Google Scholar
• Ozttirkeri H, Emekdas G, Kocabeyoglu O et al. In-vitro efficiency of isoniazid, rifampin, ethambutol and streptomycin against tuberculosis bacilli: Results of Bactec method. J Turk Microbiol Soc 1999; 29: 58–60.
   Google Scholar
• Senol G, Komtirctioglu B, Komtirctioglu A. Drug resis-tance of Mycobacterium tuberculosis in Western Turkey: a retrospective study from 1100 bed teaching hospital. Doi: 10.1016/j.jinf .2004.05.010.
   Google Scholar
• Erkan L, Sipit T, Akkalyoncu B, Gözti A et al. Cross resistance between rifampin and rifabutin [in Turkish]. J Respir Dis 2000; 11: 396–400.
   Google Scholar
• Sanbas Z, Kocagoz T, Alp A et al. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heterodublex analysis and determination of rifamycin cross resistance in rifampin resistance isolates. J Clin Microbiol 2003; 41 (2): 816-818.
   PubMed Web of Science ®Google Scholar
• Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Centers for Disease Control, Atlanta, GA. 1985.
   Google Scholar
• Heifets LB. Qualitative and quantitative drug-susceptibil-ity tests in mycobacteriology. Am Rev Respir Dis 1988; 137 (5): 1217–1222.
   PubMed Web of Science ®Google Scholar
• Sintchenko V, Chew WK, Jelfs PJ et al. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology 1999; 31 (3): 257–260.
   PubMed Web of Science ®Google Scholar
• Pubhlik BM. Problem of drug-resistant tuberculosis and the way of its solution [In Russian]. Probl Tuberk 1999; 6: 17–20.
   PubMedGoogle Scholar
• De Cian W, Sassela D, Wynne BA. Clinical experience with rifabutin in the treatment of mycobacterial infections. Scand J Infect Dis 1995; 98: 22–26.
   Google Scholar
• Frieden TR, Sterling T, Pablos-Mendez A et al. The emergence of drug-resistance tuberculosis in New York City. N Engl J Med 1993; 328 (2): 521–526.
   PubMedGoogle Scholar
• Dickinson JM, Mitchison DA. In vitro activity of new rifamycin against rifampin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68 (3): 177-182.
   Google Scholar
• Chien HP, Yu MC, Ong TF et al. In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan. J Form Med Assoc 2000; 99 (5): 408–411.
   PubMed Web of Science ®Google Scholar
• Ridzon R, Whitney CG, McKenna MT et al. Risk fac-tors for rifampin mono-resistant tuberculosis. Am Rev Respir Dis 1998; 157 (6 Pt 1): 1881-1884.
   Google Scholar
• Cavusoglu C, Karaca-Derici Y, Bilgiç A. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuber-culosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10 (7): 602–605.
   Google Scholar
• Yang B, Koga H, Ohna H et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrobial Chem 1998; 42 (4): 621-628.
   Google Scholar
• Jabes D. Effectiveness of rifabutin alone or in combina-tion with isoniazid in preventive therapy of mouse tuberculo-sis. Antimicrobial Agents Chem 1994; 38 (10): 2346–2350.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Montaner II, Natal S, Yongchaiyud P et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Rifabutin study group. Tuberc Lung Dis 1994; 75 (3): 341–347.
   Google Scholar
• Bergmann JS, Woods GL. In vitro activity of antimicro-bial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1998; 2 (8): 621–626.
   PubMed Web of Science ®Google Scholar
• Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22 Suppl 1: 50–54.
   Google Scholar